Further investigation is underway assessing the safety and efficacy of in situ vaccination with Ad-CCL21-DC in combination with anti–programmed cell death protein-1 checkpoint blockade for metastatic NSCLC (Clinicaltrials.gov: NCT03546361).31 The gene discussed is CCL21; the disease is non-small cell lung carcinoma.